Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases
The polyglutamine (polyQ) diseases are a group of inherited neurodegenerative diseases caused by the abnormal expansion of a CAG trinucleotide repeat that are translated into an expanded polyQ stretch in the disease-causative proteins. The expanded polyQ stretch itself plays a critical disease-causa...
Main Authors: | Eiko N. Minakawa, Yoshitaka Nagai |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fnins.2021.621996/full |
Similar Items
-
Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases
by: Toshihide Takeuchi, et al.
Published: (2017-10-01) -
Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease
by: Emma Hockly, et al.
Published: (2006-01-01) -
Natural Genetic Variation in Yeast Reveals That NEDD4 Is a Conserved Modifier of Mutant Polyglutamine Aggregation
by: Theodore W. Peters, et al.
Published: (2018-11-01) -
Mechanism of spreading of prion and polyglutamine aggregates and role of the cellular prion protein in Huntington’s disease
by: Costanzo, Maddalena
Published: (2012) -
Simple model systems: a challenge for Alzheimer's disease
by: Di Carlo Marta
Published: (2012-04-01)